MDC-NVA

**MDC-NVA** is an investigational Medincell pain program based on the company's long-acting injectable **BEPO** drug-delivery technology. Publicly available company materials describe it as a **perineural treatment** being developed for pain management, including **post-operative episodic pain** and **chronic post-traumatic peripheral neuropathic pain**; earlier Medincell disclosures also described it more generally as a chronic pain management program intended to help reduce opioid use. The specific active pharmaceutical ingredient and molecular target have not been publicly identified in the sources reviewed, and the program appears to have remained at the **formulation or preclinical candidate-selection stage** rather than entering clearly documented clinical development.